Christopher Haqq
2016 - Atara Biotherapeutics
In 2016, Christopher Haqq earned a total compensation of $3.3M as EVP, R&D and Chief Scientific Officer at Atara Biotherapeutics, a 34% increase compared to previous year.
Compensation breakdown
| Bonus | $154,752 |
|---|---|
| Salary | $416,000 |
| Stock Awards | $2,723,502 |
| Other | $3,768 |
| Total | $3,298,022 |
Haqq received $2.7M in stock awards, accounting for 83% of the total pay in 2016.
Haqq also received $154.8K in bonus, $416K in salary and $3.8K in other compensation.
Rankings
In 2016, Christopher Haqq's compensation ranked 2,844th out of 14,075 executives tracked by ExecPay. In other words, Haqq earned more than 79.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,844 out of 14,075 | 80th |
Division Manufacturing | 985 out of 5,489 | 82nd |
Major group Chemicals And Allied Products | 291 out of 1,895 | 85th |
Industry group Drugs | 211 out of 1,538 | 86th |
Industry Biological Products, Except Diagnostic Substances | 45 out of 279 | 84th |
Source: SEC filing on April 24, 2017.
Haqq's colleagues
We found two more compensation records of executives who worked with Christopher Haqq at Atara Biotherapeutics in 2016.